Memphis / Seattle / Cambridge / Houston / Rockville / Los Angeles / New York / /
Company
Genetix Pharmaceuticals / /
Facility
Jude Children's Research Hospital / National Cancer Institute / Texas Children’s Cancer Center / Roger Williams Hospital / Memorial Sloan-Kettering Cancer Center / Memorial SloanKettering Cancer Center / Baylor College of Medicine / M.D. Anderson Cancer Center / Fred Hutchinson Cancer Research Center / University of Pennsylvania / Anderson Cancer Center / University of California School / /
IndustryTerm
Cancer Care / cell protocols / /
MedicalCondition
Cancer / high disease / elderly / pulmonary disease / /
Organization
National Cancer Institute / Roger Williams Hospital / Baylor College of Medicine / Houston / National Institute of Health / Seattle Cancer Care Alliance / Federal Food and Drug Administration / Cancer Center / Texas Children’s Cancer Center / University of California School of Medicine / Memorial Sloan-Kettering Cancer Center / Memorial SloanKettering Cancer Center / IN CLINICAL TRIAL DESIGN Hilton Rockville Hotel & Executive Center / University of Pennsylvania / Philadelphia / Jude Children's Research Hospital / Recombinant DNA Advisory Committee / Fred Hutchinson Cancer Research Center / /
Person
Carl H. June / D. Carl H. June / Gianpietro Dotti / Scott E. Strome / Richard P. Junghans / Michel Sadelain / Laurence J. Cooper / George Coukos / D. Richard P. Junghans / Stephen M. Gottschalk / Antoni Ribas / John A. Zaia / Steven A. Rosenberg / Dario Campana / Daniel Takefman / Michael C.V. Jensen / /
NATIONAL INSTITUTES OF HEALTH (NIH) SAFETY SYMPOSIUM GENE-MODIFIED T CELLS: CHALLENGES IN CLINICAL TRIAL DESIGN Hilton Rockville Hotel & Executive Center June 15, 2010